Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
bb2121 in Multiple Myeloma Patients After Auto HCT and Maintenance Lenalidomide
NCT05032820Phase 2Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Jan 2022
- Primary completion
- Aug 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idecabtagene vicleucel in multiple myeloma (MM), sponsored by Medical College of Wisconsin. Primary endpoint: Efficacy of BCMA CAR-T Cell Therapy at 6 months. Started Jan 2022; status: completed.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05032820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032820.